TABLE 9-continued

| Additional Liposomal Elinafide Formulations | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| Sample ID | Liposome | Salt | IVR (60° C., 72 h) | Particle Size | Total Lipid (mg/ml) | Total Elinafide (mg/ml) | Lipid:Drug | 2 hr Tx [μM] (HT29) | 24 hr Tx [μM] (HT29) |
| E000389-359 | DEPC:Chol:DSPE-PEG(2000) 55:40:5 | sulfate | Very fast | 95.6 | 24.34 | 3.78 | 6.4 | 0.335 | 0.060 |
| E000389-360 | DEPC:Chol:DSPE-PEG(2000) 55:40:5 | sulfate | Very fast | 98.1 | 19.08 | 2.22 | 8.6 | 0.122 | 0.079 |
| E000389-361 | DEPC:Chol:DSPE-PEG(2000) 55:40:5 | citrate | Very fast | 87.4 | 25.58 | 3.88 | 6.6 | 0.300 | 0.095 |
| E000389-362 | DEPC:Chol:DSPE-PEG(2000) 55:40:5 | citrate | Very fast | 89.1 | 20.41 | 2.20 | 9.3 | 0.180 | 0.149 |

**[0126]** Although the foregoing has been described in some detail by way of illustration and example for purposes of clarity and understanding, one of skill in the art will appreciate that certain changes and modifications can be practiced within the scope of the appended claims. In addition, each reference provided herein is incorporated by reference in its entirety to the same extent as if each reference was individually incorporated by reference.

What is claimed is:

**1**. A liposomal composition for the treatment of cancer in a patient in need thereof comprising:

a) a liposome comprising:

i) about 50 mol % to about 70 mol % of a phosphatidylcholine lipid or mixture of phosphatidylcholine lipids;

ii) about 25 mol % to about 45 mol % of cholesterol;

iii) about 2 mol % to about 8 mol % of a PEG-lipid; and

iv) elinafide; and

b) a pharmaceutically acceptable excipient.

**2**. The liposomal composition of claim **1**, wherein the phosphatidylcholine lipid is selected from the group consisting of: palmitoyloleoylphosphatidylcholine (POPC), distearoylphosphatidylcholine (DSPC), dimyristoylphosphatidylcholine (DMPC), dipalmitoylphosphatidylcholine (DPPC), hydrogenated soy phosphatidylcholine (HSPC), 1,2-diarachidoyl-sn-glycero-3-phosphocholine, and mixtures thereof.

**3**. The liposomal composition of claim **2**, wherein the phosphatidylcholine lipid is DSPC.

**4**. The liposomal composition of claim **1**, wherein the PEG-lipid is selected from the group consisting of distearoyl-phosphatidylethanolamine-N-[methoxy(polyethene glycol)-2000](DSPE-PEG-2000) and distearoyl-phosphatidylethanolamine-N-[methoxy(polyethene glycol)-5000] (DSPE-PEG-5000).

**5**. The liposomal composition of claim **1**, wherein the liposome comprises about 55% of DSPC; about 40% cholesterol; and about 5% DSPE-PEG-2000.

**6**. The liposomal composition of claim **1**, wherein the ratio of the total lipid weight to the elinafide is about 1:0.1 to 1:1.

**7**. The liposomal composition of claim **1**, wherein the liposome has a volume mean particle size of about 125 nm or less.

**8**. The liposomal composition of claim **7**, wherein the liposome has a volume mean particle size of about 50 nm about 100 nm.

**9**. The liposomal composition of claim **1**, wherein less than 10% of the elinafide is released from the liposome within 20 hours.

**10**. The liposomal composition of claim **1**, wherein the composition has an $IC_{50}$ of about 10.0 μM or less after 2 hours in HT29 cells.

**11**. The liposomal composition of claim **1**, wherein the composition has an $IC_{50}$ of about 1.0 μM or less after 24 hours in HT29 cells.

**12**. The liposomal composition of claim **1**, wherein the composition has a plasma AUC greater than free elinafide or a clearance rate (Cl) less than free elinafide.

**13**. The liposomal composition of claim **1**, wherein composition inhibited tumor growth greater than free elinafide.

**14**. The liposomal composition of claim **1**, wherein the composition delayed tumor growth greater than free elinafide.

**15**. The liposomal composition of claim **1**, wherein the composition does not induce or has reduced muscle myopathy compared to free elinafide.

**16**. A method of treating cancer in a patient in need thereof, comprising the steps of:

(a) administering to the patient in need thereof a liposomal composition comprising

i) a liposome comprising:

1) about 50 mol % to about 70 mol % of a phosphatidylcholine lipid or mixture of phosphatidylcholine lipids;

2) about 25 mol % to about 45 mol % of cholesterol;

3) about 2 mol % to about 8 mol % of a PEG-lipid; and

4) elinafide; and

ii) a pharmaceutically acceptable excipient;

wherein the administration of the liposomal composition has a reduced occurrence of muscle myopathy in the patient.

**17**. The method of treating cancer of claim **16**, wherein an initial dose of the liposomal composition is from about 0.001 mg/kg to about 1000 mg/kg daily.

**18**. The method of treating cancer of claim **17**, wherein the initial dose of the liposomal composition is from about 1 g/kg to about 100 mg/kg daily.

**19**. The method of treating cancer of claim **16**, wherein a daily dose of the liposomal composition is 3, 6, 12, 24, 48, 80, 120, 160, 190, 225, 270, or 320 mg/$M^2$.

* * * * *